Outcomes in the Japan subgroup were in line with the findings in the global CAPItello-291 population further supporting the clinical benefit of capivasertib–fulvestrant in treating patients with HR-positive/HER2-negative advanced breast cancer that has progressed on, or after, an endocrine-based regimen, including patients from Japan. The gene discussed is ERBB2; the disease is breast carcinoma.